GLP-1 agonists that have beneficial effects on glycemic control, weight gain and blood pressure in type 2 diabetes should continue to be considered for clinical trials in PCOS to assess their ability to chronically improve the multiple manifestations of the syndrome. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.